.Pharmacolibrary.Drugs.C_CardiovascularSystem.C07F_BetaBlockingAgentsOtherCombinations.C07FB03_AtenololAndNifedipine.AtenololAndNifedipine

Information

Combination of atenolol, a selective beta-1 adrenergic blocker, and nifedipine, a dihydropyridine calcium channel blocker. Used for the management of hypertension and angina pectoris. The drug is approved and used in clinical practice today, particularly when single-agent therapy is insufficient.

Pharmacokinetics

No direct pharmacokinetic studies or population PK models published for the fixed dose combination of atenolol and nifedipine (ATC C07FB03) were found. Individual pharmacokinetics for each agent are well-characterized, but specific combination PK parameters are not reported in the literature for healthy or patient populations.

References

1. Langtry, HD, & Markham, A (1997). Lisinopril. A review of its pharmacology and clinical efficacy in elderly patients. Drugs & aging 10(2) 131–166. DOI:10.2165/00002512-199710020-00006 PUBMED:https://pubmed.ncbi.nlm.nih.gov/9061270

2. Larochelle, P (1990). Hypertension in the elderly. Cardiovascular drugs and therapy 4 Suppl 5 947–950. DOI:10.1007/BF02018298 PUBMED:https://pubmed.ncbi.nlm.nih.gov/2076405

3. McTavish, D, et al., & Sorkin, EM (1993). Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 45(2) 232–258. DOI:10.2165/00003495-199345020-00006 PUBMED:https://pubmed.ncbi.nlm.nih.gov/7681374

Revisions

• 06/2025 initial generated model